Welgene Biotech Co.,Ltd.

Taipei Exchange 6661.TWO

Welgene Biotech Co.,Ltd. Interest Coverage Ratio for the year ending December 31, 2023: -0.16

Welgene Biotech Co.,Ltd. Interest Coverage Ratio is -0.16 for the year ending December 31, 2023, a -100.27% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

Welgene Biotech Co.,Ltd. Interest Coverage Ratio for the year ending December 31, 2022 was 59.12, a 26.22% change year over year.
Welgene Biotech Co.,Ltd. Interest Coverage Ratio for the year ending December 31, 2021 was 46.84, a -15.86% change year over year.
Welgene Biotech Co.,Ltd. Interest Coverage Ratio for the year ending December 31, 2020 was 55.67, a -54.78% change year over year.
Welgene Biotech Co.,Ltd. Interest Coverage Ratio for the year ending December 31, 2019 was 123.09, a 113.25% change year over year.

Key data

Date	Interest Coverage Ratio	Debt to Equity Ratio	Interest Expense To Sales	Inventory Turnover Ratio

Taipei Exchange: 6661.TWO

Welgene Biotech Co.,Ltd.

CEO	Dr. Yi Xing Lin
IPO Date	Oct. 23, 2017
Location	Taiwan
Headquarters	No. 3, Yuanyuan Street
Employees	80
Sector	Health Care
Industries Biotechnology Research & Consulting

Description

Welgene Biotech Co.,Ltd. provides genetic testing services. The company offers research services, including sequencing, microarray, qPCR verification, nucleic acid extraction/QC, LCM single cell experiment, and bioinformatics analysis services; and Cytoscan, an array-based comparative genomic hybridization. It also provides reagents, consumable supplies, and instruments, as well as software services. The company was founded in 2003 and is based in Taipei City, Taiwan.

Key trends

Past 5 years